ACHV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ACHV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Achieve Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $16.73 Mil. Achieve Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.01 Mil. Achieve Life Sciences's annualized EBITDA for the quarter that ended in Dec. 2023 was $-18.53 Mil. Achieve Life Sciences's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.90.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for Achieve Life Sciences's Debt-to-EBITDA or its related term are showing as below:
The historical data trend for Achieve Life Sciences's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Achieve Life Sciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Debt-to-EBITDA | Get a 7-Day Free Trial | -0.02 | -0.01 | -0.46 | -0.40 | -0.63 |
Achieve Life Sciences Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Debt-to-EBITDA | Get a 7-Day Free Trial | -0.38 | -0.49 | -0.53 | -0.65 | -0.90 |
For the Biotechnology subindustry, Achieve Life Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Achieve Life Sciences's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Achieve Life Sciences's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Achieve Life Sciences's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (16.725 | + | 0.006) | / | -26.734 | |
= | -0.63 |
Achieve Life Sciences's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (16.725 | + | 0.006) | / | -18.528 | |
= | -0.90 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.
Achieve Life Sciences (NAS:ACHV) Debt-to-EBITDA Explanation
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
Be Aware
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of Achieve Life Sciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
John Bencich | officer: CFO and PFO | 2401 FOURTH AVENUE, SUITE 1050, SEATTLE WA 98121 |
Stuart Duty | director | 22722 29TH DR SE, SUITE 100, BOTHELL WA 98021 |
Thomas Sellig | director | 22722 29TH DR SE, SUITE 100, BOTHELL WA 98021 |
Thomas Braxton King | director | 91 JAMES AVENUE, ATHERTON CA 94027 |
Dialectic Life Sciences Spv Llc | 10 percent owner | C/O DIALECTIC LS MANAGER LLC, 119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853 |
Dialectic Ls Manager Llc | 10 percent owner | 119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853 |
John Fichthorn | 10 percent owner | C/O DIALECTIC CAPITAL MANAGEMENT, LLC, 17 STATE STREET, SUITE 3930, NEW YORK NY 10004 |
Dialectic Capital Management, Lp | 10 percent owner | 119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853 |
Dialectic Partners, Llc | 10 percent owner | 2ND FLOOR 119 ROWAYTON AVE, NORWALK CT 06853 |
Vaughn B Himes | director | C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021 |
Financial Group Svb | 10 percent owner | 2270 SAND HILL ROAD, MENLO PARK CA 94025 |
Svb Innovation Credit Partners Viii, Llc | 10 percent owner | 2770 SAND HILL ROAD, MENLO CITY CA 94025 |
Svb Innovation Credit Fund Viii, L.p. | 10 percent owner | C/O SVB INNOVATION CREDIT PARTNERS VIII, 2770 SAND HILL ROAD, MENLO PARK CA 94025 |
Innovation Credit Fund Viii-a, L.p. | 10 percent owner | 2770 SAND HILL ROAD, MENLO PARK CA 94025 |
Svb Innovation Credit Partners Viii-a, Llc | 10 percent owner | 2770 SAND HILL ROAD, MENLO CITY CA 94025 |
From GuruFocus
By Value_Insider Value_Insider • 11-08-2022
By GlobeNewswire GlobeNewswire • 01-27-2023
By Marketwired • 08-01-2023
By PRNewswire • 12-12-2023
By Stock market mentor Stock market mentor • 02-02-2023
By sperokesalga sperokesalga • 03-17-2023
By sperokesalga sperokesalga • 03-02-2023
By Marketwired • 07-11-2023
By Stock market mentor Stock market mentor • 02-07-2023
By sperokesalga sperokesalga • 06-06-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.